Genealogy and clinical course of catecholaminergic polymorphic ventricular tachycardia caused by the ryanodine receptor type 2 P2328S mutation

被引:3
|
作者
Koponen, Mikael [1 ,2 ]
Marjamaa, Annukka [1 ]
Tuiskula, Annukka M. [2 ,3 ,4 ]
Viitasalo, Matti [1 ]
Nallinmaa-Luoto, Terhi [5 ]
Leinonen, Jaakko T. [6 ]
Widen, Elisabeth [6 ]
Toivonen, Lauri [1 ]
Kontula, Kimmo [2 ,3 ]
Swan, Heikki [2 ]
机构
[1] Helsinki Univ Hosp, Heart & Lung Ctr, Helsinki, Finland
[2] Univ Helsinki, Helsinki, Finland
[3] Helsinki Univ Hosp, Dept Med, Helsinki, Finland
[4] Helsinki Univ Hosp, Genet Lab, HUSLAB, Helsinki, Finland
[5] Univ Turku, Turku, Finland
[6] Univ Helsinki, Inst Mol Med Finland, FIMM, Helsinki, Finland
来源
PLOS ONE | 2020年 / 15卷 / 12期
关键词
SUDDEN CARDIAC DEATH; MOLECULAR CHARACTERIZATION; BETA-BLOCKERS; ARRHYTHMIAS; GENE; ASSOCIATION; FLECAINIDE; CHILDREN; THERAPY; EVENTS;
D O I
10.1371/journal.pone.0243649
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe inherited arrhythmic disease associated with a risk of syncope and sudden cardiac death (SCD). Aims We aimed at identifying RYR2 P2328S founder mutation carriers and describing the clinical course associated with the mutation. Methods The study population was drawn from the Finnish Inherited Cardiac Disorder Research Registry, and from the present genealogical study. Kaplan-Meier graphs, log-rank test and Cox regression model were used to evaluate the clinical course. Results Genealogical study revealed a common ancestor couple living in the late 17(th) century. A total of 1837 living descendants were tested for RYR2 P2328S mutation unveiling 62 mutation carriers aged mean 3923 years old. No arrhythmic deaths were documented among genotyped subjects, but 11 SCDs were detected in non-genotyped family members since 1970. Three genotyped patients (5%) suffered an aborted cardiac arrest (ACA), and 15 (25%) had a syncope triggered by exercise or stress. Rate of cardiac events was higher among patients who in exercise stress test showed a maximum rate of premature ventricular contractions >30/min (68% vs 17%, p<0.01; hazard ratio = 7.1, p = 0.02), in comparison to patients without the respective finding. A cardioverter-defibrillator (ICD) was implanted to 13 (22%) patients, with an appropriate ICD shock in four (31%) subjects. All ICD shocks, one ACA, and one syncope occurred during -blocker medication. Conclusions Previously undiagnosed CPVT patients may be identified by well-conducted genealogical studies. The RYR2 P2328S mutation causes a potentially severe phenotype, but its expression is variable, thus calling for additional studies on modifying factors.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Clinical Course in Carriers of the Ryanodine Receptor Type 2 P2328S Mutation Underlying Catecholaminergic Polymorphic Ventricular Tachycardia
    Koponen, Mikael
    Marjamaa, Annukka
    Kontula, Kimmo
    Swan, Heikki
    CIRCULATION, 2019, 140
  • [2] Catecholaminergic Polymorphic Ventricular Tachycardia Is Caused by Mutation-Linked Defective Conformational Regulation of the Ryanodine Receptor
    Uchinoumi, Hitoshi
    Yano, Masafumi
    Suetomi, Takeshi
    Ono, Makoto
    Xu, Xiaojuan
    Tateishi, Hiroki
    Oda, Tetsuro
    Okuda, Shinichi
    Doi, Masahiro
    Kobayashi, Shigeki
    Yamamoto, Takeshi
    Ikeda, Yasuhiro
    Ohkusa, Tomoko
    Ikemoto, Noriaki
    Matsuzaki, Masunori
    CIRCULATION RESEARCH, 2010, 106 (08) : 1413 - 1424
  • [3] Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function
    Zhao, Yan-Ting
    Valdivia, Carmen R.
    Gurrola, Georgina B.
    Powers, Patricia P.
    Willis, B. Cicero
    Moss, Richard L.
    Jalife, Jose
    Valdivia, Hector H.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (13) : E1669 - E1677
  • [4] A case report of familial catecholaminergic polymorphic ventricular tachycardia with a novel mutation in the ryanodine receptor 2
    Shoji, Yoshikuni
    Hayashida, Satoshi
    Masuda, Hikaru
    Tachibana, Eizo
    Okumura, Yasuo
    EUROPEAN HEART JOURNAL-CASE REPORTS, 2024, 8 (12)
  • [5] Novel Ryanodine Receptor 2 Mutation Associated with a Severe Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia
    LaPage, Martin J.
    Russell, Mark W.
    Bradley, David J.
    Dick, Macdonald, II
    JOURNAL OF PEDIATRICS, 2012, 161 (02): : 362 - 364
  • [6] Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia
    Wangueemert, Fernando
    Bosch Calero, Cristina
    Perez, Carmelo
    Campuzano, Oscar
    Beltran-Alvarez, Pedro
    Scornik, Fabiana S.
    Iglesias, Anna
    Berne, Paola
    Allegue, Catarina
    Ruiz Hernandez, Pablo M.
    Brugada, Josep
    Perez, Guillermo J.
    Brugada, Ramon
    HEART RHYTHM, 2015, 12 (07) : 1636 - 1643
  • [7] Characterization of a novel mutation in the cardiac ryanodine receptor that results in catecholaminergic polymorphic ventricular tachycardia
    Jiang, Dawei
    Jones, Peter P.
    Davis, Darryl R.
    Gow, Robert
    Green, Martin S.
    Birnie, David H.
    Chen, S. R. Wayne
    Gollob, Michael H.
    CHANNELS, 2010, 4 (04) : 302 - 310
  • [9] Ryanodine receptor 2 mutation: Not only catecholaminergic polymorphic ventricular tachycardia but also epileptiform discharges in electroencephalogram
    She, Yingfang
    Li, Yide
    Yu, Hang
    Zhou, Liemin
    NEUROLOGY ASIA, 2020, 25 (03) : 387 - 394
  • [10] Complex atrial arrhythmias as first manifestation of catecholaminergic polymorphic ventricular tachycardia: an unusual course in a patient with a new mutation in ryanodine receptor type 2 gene
    Lawrenz, Wolfgang
    Krogmann, Otto N.
    Wieczorek, Marcus
    CARDIOLOGY IN THE YOUNG, 2014, 24 (04) : 741 - 744